OBJECTIVE: This study aims to determine the association between hyperglycemia, insulin therapy, and severe retinopathy of prematurity (ROP) in extremely low-birth-weight (ELBW) infants. STUDY DESIGN: In this retrospective database study, we included all ELBW infants who were ≤ 32 weeks gestational age (GA). We excluded infants without any ophthalmology evaluation and infants who died before 28 days of life. A multivariable model was constructed to determine the association between hyperglycemia, insulin use, and severe ROP. We defined hyperglycemia as blood glucose (BG) > 180 mg/dL. Covariates were GA, small for GA status, discharge year, sex, Apgar score at 5 minutes, mechanical ventilation, oxygen use, bacteremia, and postnatal steroid exposure. We defined severe ROP as ROP requiring bevacizumab, cryotherapy, laser therapy, or vitrectomy. Sensitivity analysis using BG > 150 mg/dL and > 200 mg/dL was performed. RESULTS: A total of 24,548 infants were included; 2,547 (10%) had severe ROP. Hyperglycemia alone was not associated with severe ROP (odds ratio [OR], 0.88; 95% confidence interval [CI], 0.66-1.17). Hyperglycemia and insulin use were not associated with severe ROP (OR, 1.43; 95% CI, 0.91-2.23). BG > 150 mg/dL and insulin use were associated with severe ROP (OR, 1.34; 95% CI, 1.02-1.76). CONCLUSIONS: Hyperglycemia alone was not associated with severe ROP in ELBW infants. However, we did observe a possible trend between the use of insulin and severe ROP. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.
OBJECTIVE: This study aims to determine the association between hyperglycemia, insulin therapy, and severe retinopathy of prematurity (ROP) in extremely low-birth-weight (ELBW) infants. STUDY DESIGN: In this retrospective database study, we included all ELBW infants who were ≤ 32 weeks gestational age (GA). We excluded infants without any ophthalmology evaluation and infants who died before 28 days of life. A multivariable model was constructed to determine the association between hyperglycemia, insulin use, and severe ROP. We defined hyperglycemia as blood glucose (BG) > 180 mg/dL. Covariates were GA, small for GA status, discharge year, sex, Apgar score at 5 minutes, mechanical ventilation, oxygen use, bacteremia, and postnatal steroid exposure. We defined severe ROP as ROP requiring bevacizumab, cryotherapy, laser therapy, or vitrectomy. Sensitivity analysis using BG > 150 mg/dL and > 200 mg/dL was performed. RESULTS: A total of 24,548 infants were included; 2,547 (10%) had severe ROP. Hyperglycemia alone was not associated with severe ROP (odds ratio [OR], 0.88; 95% confidence interval [CI], 0.66-1.17). Hyperglycemia and insulin use were not associated with severe ROP (OR, 1.43; 95% CI, 0.91-2.23). BG > 150 mg/dL and insulin use were associated with severe ROP (OR, 1.34; 95% CI, 1.02-1.76). CONCLUSIONS: Hyperglycemia alone was not associated with severe ROP in ELBW infants. However, we did observe a possible trend between the use of insulin and severe ROP. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.
Authors: Jeffrey D Horbar; Joseph H Carpenter; Gary J Badger; Michael J Kenny; Roger F Soll; Kate A Morrow; Jeffrey S Buzas Journal: Pediatrics Date: 2012-05-21 Impact factor: 7.124
Authors: Kathryn Beardsall; Sophie Vanhaesebrouck; Amanda L Ogilvy-Stuart; Christine Vanhole; Chris R Palmer; Ken Ong; Mirjam vanWeissenbruch; Paula Midgley; Mike Thompson; Marta Thio; Luc Cornette; Iviano Ossuetta; Isabel Iglesias; Claire Theyskens; Miranda de Jong; Bryan Gill; Jag S Ahluwalia; Francis de Zegher; David B Dunger Journal: J Pediatr Date: 2010-06-08 Impact factor: 4.406
Authors: A J van Sorge; J U M Termote; M J de Vries; F N Boonstra; C Stellingwerf; N E Schalij-Delfos Journal: Br J Ophthalmol Date: 2011-02-10 Impact factor: 4.638
Authors: Kathryn Beardsall; Sophie Vanhaesebrouck; Amanda L Ogilvy-Stuart; Christine Vanhole; Christopher R Palmer; Mirjam van Weissenbruch; Paula Midgley; Michael Thompson; Marta Thio; Luc Cornette; Iviano Ossuetta; Isabel Iglesias; Claire Theyskens; Miranda de Jong; Jag S Ahluwalia; Francis de Zegher; David B Dunger Journal: N Engl J Med Date: 2008-10-30 Impact factor: 91.245
Authors: N Margreth van der Lugt; Vivianne E H J Smits-Wintjens; Paul H T van Zwieten; Frans J Walther Journal: BMC Pediatr Date: 2010-07-20 Impact factor: 2.125
Authors: Sang Jin Kim; Alexander D Port; Ryan Swan; J Peter Campbell; R V Paul Chan; Michael F Chiang Journal: Surv Ophthalmol Date: 2018-04-19 Impact factor: 6.048